Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Talaris Therapeutics Inc.

www.regenerex.com

Latest From Talaris Therapeutics Inc.

Finance Watch: Billions Flow Into Biopharma Via Three New Investment Funds

Blackstone raised $3.44bn of a $4.58bn life science fund, while HealthCare Royalty Partners raised $1.8bn and MVM closed a $325m fund. Also, 20 private drug developers raised $20m or more, but three public biopharma firms unveiled restructuring plans. 

Financing Business Strategies

Venture Funding Deals: CNS Plays Are Attracting Investment

Polyneuron, Synerkine, Harmony, EIP Pharma and AITI Life Sciences all raised cash in recent weeks to tackle various conditions involving the nervous system. More recent venture funding deals... 

Financing StartUps and SMEs

Finance Watch: Hatteras Nearly Halfway To $200m Goal For New Early-Stage VC Fund

Private Company Edition: General Partner Clay Thorp says the venture capital firm's longtime focus on seed and early-stage investments is unchanged and bolstered by market fundamentals. Also, Talaris and insitro each raised $100m Series A rounds, plus other financings.

Financing StartUps and SMEs

Shedding Earlier Fears, Pharma Takes A Fresh Look At Cell, Gene Therapies

The early successes enjoyed by new autologous, cell-based cancer therapies, as well as new advances in gene therapy and regenerative medicine, have reignited interest at Big Pharma in these advanced treatments, said partnering executives at the recent Therapeutic Area Partnerships meeting in Boston.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Renal System
  • Alias(es)
  • Regenerex LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Talaris Therapeutics Inc.
  • Senior Management
  • Scott Requadt, CEO
    Nancy Krieger, MD, CMO
  • Contact Info
  • Talaris Therapeutics Inc.
    Phone: (502) 569-1059
    201 East Jefferson St.
    Ste. 110
    Louisville, KY 40202
    USA
UsernamePublicRestriction

Register